279 articles with Orexo AB
The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.
2018 was a pivotal year for Orexo
Orexo AB announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis's generic Zubsolv products infringe Orexo's U.S. patent No. 8,940,330
Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal
Orexo AB today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo's novel naloxone nasal spray formulations intended for opioid overdose reversal.
Orexo AB today announces that the Company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for the treatment of opioid dependence in all territories outside the United States from its current partner, Mundipharma, on April 13, 2019.
Orexo AB (publ.) is today hosting the Company's Capital Markets Day for investors, analysts and media in Stockholm, Sweden.
US Court of Appeals Denies Actavis's Petition for Rehearing Regarding Validity of the Zubsolv® Patent
Orexo AB today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC's (Actavis) combined petition for panel rehearing and rehearing en banc in the case regarding Orexo's Zubsolv US patent 8,940,330.
Orexo to Host a Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Keynote Speaker
Orexo will provide an update on the Company's strategy for growth, market trends and position and its increased focus on R&D, including new innovative formulation technologies.
The win in the patent litigation strengthen Orexo's long term business opportunities
Save the Date: Orexo to Host Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Key Note Speaker
Orexo AB today announces that the Company will host a Capital Markets Day for investors, analysts and media in Stockholm City, Sweden, on Thursday December 6, 2018.
Orexo AB announces today that the company appoints Joseph DeFeo as the company's new Chief Financial Officer (CFO) from November 1, 2018.
Although the dominant story in biopharma patent litigation was the federal appeals court backing the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University over the University of California (UC) on CRISPR patents, there have been other patent decisions of note t...
Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo's long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016.
Zubsolv® continues its strong performance
Number of Shares and Votes in Orexo Has Changed as a Result of the Issue and Repurchase of 325,000 Class C Shares
The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15, 2018.
Orexo AB announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet)
Zubsolv US growth of 26 percent in local currency
The annual general meeting in Orexo AB (publ) on 12 April 2018 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be seven with no deputy board members.
Orexo's Annual Report for the 2017 fiscal year has been published and can be downloaded on the company's website, www.orexo.com (investors/reports, presentations and audiocasts).
Total net revenues SEK 191.0 million (184.7).